Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne B Hendrix

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2016
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trialsJinping Wang, Veronika Logovinsky, Suzanne B Hendrix, et al.
Journal of Alzheimer'S Disease : JAD|September 15, 2025
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trialBenjamin Haaland, Samuel P Dickson, Agustin Fernández Santana, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 27, 2025
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's diseaseGarrett B Duncan, Samuel P Dickson, Johanne M Kaplan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's diseaseJessica B Langbaum, Suzanne B Hendrix, Napatkamon Ayutyanont, et al.
Alzheimer'S Research & Therapy|May 29, 2020
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's diseaseJessica B Langbaum, Noel N Ellison, Angelika Caputo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 8, 2021
GenoRisk: A polygenic risk score for Alzheimer's diseaseSamuel P Dickson, Suzanne B Hendrix, Bruce L Brown, et al.
Ebiomedicine|July 1, 2023
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a studyHui Jing Yu, Samuel P Dickson, Pei-Ning Wang, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2016
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trialsJinping Wang, Veronika Logovinsky, Suzanne B Hendrix, et al.
Journal of Alzheimer'S Disease : JAD|September 15, 2025
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trialBenjamin Haaland, Samuel P Dickson, Agustin Fernández Santana, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 27, 2025
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's diseaseGarrett B Duncan, Samuel P Dickson, Johanne M Kaplan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's diseaseJessica B Langbaum, Suzanne B Hendrix, Napatkamon Ayutyanont, et al.
Alzheimer'S Research & Therapy|May 29, 2020
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's diseaseJessica B Langbaum, Noel N Ellison, Angelika Caputo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 8, 2021
GenoRisk: A polygenic risk score for Alzheimer's diseaseSamuel P Dickson, Suzanne B Hendrix, Bruce L Brown, et al.
Ebiomedicine|July 1, 2023
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a studyHui Jing Yu, Samuel P Dickson, Pei-Ning Wang, et al.
Pageof 4